GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and immune-related adverse events across cancer types in people with type 2 diabetes: a target-trial emulation
Chan SH, Li PY, Li PH, et al.
Diabetes Res Clin Pract. 2025:113073.
Leggi


